Del Mar, California, United States
Biopharmaceutical executive with extensive commercial and general management expertise delivering growth across multiple therapeutic categories, medical devices, lifecycle stages and regions. Over 30 years of experience in roles that range from CEO of a small, private, clinical stage company to President of large enterprises with direct responsibility for $8B revenues. Currently focused on advising executive teams, investors, and boards to build great companies in life sciences. Core competencies cluster around strategy, operational execution, and leadership. Key highlights include: • Built high functioning, global cross-functional teams including R&D, tech ops, clinical, regulatory, quality, legal, finance and customer facing teams to deliver on key milestones. • Differentiating flagship brands in competitive markets by translating market insights to drive growth. Built innovative go-to-market business models and tactical platforms to optimize product launches. • Create compelling company mission statements and vision to align internal and external stakeholders. Strong record of attracting, developing and retention of talent with a keen focus on diversity. • Proactive board engagement to shape strategic decisions and capital formation activities. Track record of success in transforming stagnant businesses to accelerate revenue.
ViaCyte is a regenerative medicine company focused on the discovery, development, and commercialization of novel cell replacement therapies to treat human diseases. Transformed strategic plans and execution priorities to enhance operational discipline. Refreshed company vision and communication platforms to effectively raise capital and align external stakeholders. Implemented management processes to support R&D, clinical development, and regulatory strategies leading to efficient resource allocation. Invested in new product innovation. Active engagement with the board to shape strategic decisions and future financing activities, resulting in $320 million merger with Vertex Pharmaceuticals.
Acadia is focused on delivering innovative therapies to address major unmet needs in neuroscience. Transformed the commercial capabilities and strategies to accelerate the launch trajectory of NUPLAZID. Launched an integrated DTC campaign, executed an expansion of the Long-Term Care business unit, and optimized the patient access service model leading to +65% year over year revenue growth. Successfully led the organization through challenging media and regulatory events by building a cross-functional response team that executed key market-shaping tactics to restore stakeholder confidence and brand stability.
Janssen Immunology is a leading biotech company dedicated to finding therapies for serious autoimmune and inflammatory diseases.Successfully led multi-billion-dollar business unit though unprecedented market challenges and increased complexity. Implemented new strategic platforms and commercial innovation models for growth. Revised the talent agenda to refresh leadership to revitalize sense of urgency fueling new product launches and competitive resilience. Negotiated with payers to expand access and implemented novel contracting strategies. Core metrics such as new patient starts and brand profitability consistently exceeded plan leading to year over year growth exceeding $1B.
Janssen CNS focused on therapies that help people with mental illness. Led the expansion of the novel market access unit “Janssen Connect” to support Long Acting Injectables (LAI) growth. Leveraged insight-based marketing strategies to drive 60% year over year growth for LAIs. Developed launch readiness plans for disease modifying Alzheimer’s MAB. Rejuvenated organizational culture leading to record levels of engagement and employee retention.
Veridex is the leading diagnostic company focused on Circulating Tumor Cells.Rebuilt organizational effectiveness and competency models to attract top talent. Launched novel business-to-business unit as new source of revenue. Secured investment for next generation diagnostic device from Mass General. Realigned product portfolio, shutting down unprofitable platforms and out-licensing non-core technologies. Created reimbursement strategies and tactics to reverse negative access policies. Delivered revenue increase of 36% year over year.